Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00241_DB01242_nanopub.RAbr8la49aAWHeHmIgmO57BZEqp4-PV0LpnZQDrtzz7zE#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00241_DB01242 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00241_DB01242 label "DDI between Butalbital and Clomipramine - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation. [drugbank_resource:DB00241_DB01242]" assertion.
- drugbank_resource:DB00241_DB01242 identifier "drugbank_resource:DB00241_DB01242" assertion.
- drugbank_resource:DB00241_DB01242 title "DDI between Butalbital and Clomipramine - Barbiturates such as butalbital may increase the metabolism of tricyclic antidepressants such as clomipramine. Monitor for decreased therapeutic effects of tricyclic antidepressants if a barbiturate is initiated/dose increased, or increased effects if a barbiturate is discontinued/dose decreased. The tricyclic antidepressant dosage will likely need to be increased during concomitant barbiturate therapy, and reduced upon barbiturate discontinuation." assertion.
- drugbank:DB01242 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00241_DB01242 assertion.
- drugbank:DB00241 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00241_DB01242 assertion.